Fairvalue-Calculator Fairvalue-Calculator
EN DE

T&R Biofab Co (246710) Fair Value & Analysis

Healthcare · KR · Market cap 65.6B KRW

Price1,934 KRW
Fair Value1,362 KRW
Upside-29.6%
Quality95/100
Evidence: Low Range 1,021 KRW – 1,702 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

T&R Biofab Co (246710) currently trades at 1,934 KRW, while our model-based Fair Value estimate is 1,362 KRW — implying the stock looks roughly 29.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is T&R Biofab Co (246710) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1,362 KRW versus a price of 1,934 KRW — about −30% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 246710?
Our 21-model fair value for T&R Biofab Co is 1,362 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 1,934 KRW.
What is the quality score of 246710?
T&R Biofab Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.